Cargando…
Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials
BACKGROUND: Two large-scale efficacy studies with the recombinant yellow fever-17D–dengue virus, live-attenuated, tetravalent dengue vaccine (CYD-TDV) candidate undertaken in Asia (NCT01373281) and Latin America (NCT01374516) demonstrated significant protection against dengue disease during two year...
Autores principales: | Harenberg, Anke, de Montfort, Aymeric, Jantet-Blaudez, Frédérique, Bonaparte, Matthew, Boudet, Florence, Saville, Melanie, Jackson, Nicholas, Guy, Bruno |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4961416/ https://www.ncbi.nlm.nih.gov/pubmed/27459266 http://dx.doi.org/10.1371/journal.pntd.0004830 |
Ejemplares similares
-
Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4
por: Barban, Veronique, et al.
Publicado: (2018) -
Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial
por: Park, Juliana, et al.
Publicado: (2021) -
Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination
por: Vigne, Claire, et al.
Publicado: (2017) -
An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques
por: Lecouturier, Valérie, et al.
Publicado: (2020) -
Perspectives in Virology, III
por: Isacson, Peter
Publicado: (1964)